Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, it offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.
Stock data | 2023 | Change |
---|---|---|
Price | $390.91 | N/A |
Market Cap | $11.99B | N/A |
Shares Outstanding | 30.68M | -5.26% |
Employees | 5.80K | N/A |
Valuation | 2023 | Change |
---|---|---|
P/S Ratio | 6.36 | N/A |
Earnings | 2023 | Change |
---|---|---|
Revenue | $1.89B | N/A |
Earnings | $282.81M | N/A |
Gross Margin | 0.2781 | N/A |
Operating Margin | 0.1786 | N/A |
Net income margin | 0.15 | N/A |